Gene replacement therapy in the central nervous system: Viral vector-mediated therapy of global neurodegenerative disease
Neuwelt (E.A.), Pagel (M.A.), Geller (A.) & Muldoon (L.L.)
Source: Behavioral and Brain Sciences, 18.1, March 1995, pp. 1-9
Paper - Abstract

Paper StatisticsColour-ConventionsDisclaimer

First of a set of articles, which were supposed to be introduced by Cordo, p: "Controversies in Neuroscience II: Neural Transplantation1: Introduction", but this wasn't filed in the relevant copy of Behavioral and Brain Sciences.

BBS-Online Abstract

  1. This target article describes the current state of global gene replacement in the brain through the use of viral vectors and it assesses possible solutions to some of the many problems inherent in gene therapy for the central nervous system (CNS).
  2. Gene replacement therapy is a way to generate normal human proteins in deficient cells, making cures possible for certain genetically inherited enzyme deficiences, metabolic diseases, and cancers.
  3. The two major issues to be addressed are the delivery of genetic material to the brain and the expression of recombinant genetic material in CNS target cells. Focal inoculation of recombinant virions or other genetic vectors has limitations when there is global brain disease.
  4. A new blood-brain-barrier (BBB) disruption technique, in which hypertonic mannitol transiently shrinks the BBB endothelium, allows the passage of high molecular weight compounds and even viruses. CNS gene therapy will require a viral vector system that allows long-term, nontoxic gene expression in neurons or glial cells.
  5. Retroviral vectors have limitations in CNS gene replacement, although they are suitable for expressing recombinant genes in intracerebral grafts, or toxic genes in brain tumors. Mutant neurotropic viruses with reduced neurotoxicity (e.g., defective herpes simplex virus type 1 [HSV-1], the HSV-1 amplicon vector system we have developed, or adenovirus mutants) have potential for direct treatment of neurons. Injecting these vectors into rodent brains can lead to the stable expression of foreign genetic material in postmitotic neuronal cells.
  6. We discuss our BBB disruption delivery technique, our defective HSV-1 aplicon vector system, and our feline model for the neuronal lysosomal storage disorder Gm2-gangliosidosis (Sandhoff disease), which may prove to be a useful model system for CNS gene therapy.

Text Colour Conventions (see disclaimer)

  1. Blue: Text by me; © Theo Todman, 2019
  2. Mauve: Text by correspondent(s) or other author(s); © the author(s)

© Theo Todman, June 2007 - Jan 2019. Please address any comments on this page to File output:
Website Maintenance Dashboard
Return to Top of this Page Return to Theo Todman's Philosophy Page Return to Theo Todman's Home Page